Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Iterum Therapeutics plc ITRM
$1.18
+$0.05 (4.42%)
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
14457986.00000000
-
week52high
7.02
-
week52low
0.60
-
Revenue
0
-
P/E TTM
0
-
Beta
1.60503900
-
EPS
-3.41000000
-
Last Dividend
0.00000000
-
Next Earnings Date
16 мар 2023 г. в 12:30
Описание компании
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Gabelli & Co. | Hold | Sell | 27 июл 2021 г. |
| HC Wainwright & Co. | Neutral | Buy | 26 июл 2021 г. |
| Gabelli & Co. | Hold | Sell | 28 мая 2021 г. |
| HC Wainwright & Co. | Buy | Neutral | 15 мар 2021 г. |
| SVB Leerink | Market Perform | Market Perform | 01 окт 2020 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| HUNT RONALD | D | 0 | 1197 | 01 янв 2023 г. |
| HUNT RONALD | A | 4030 | 1197 | 01 янв 2023 г. |
| Dunne Michael W. | D | 0 | 761 | 01 янв 2023 г. |
| Dunne Michael W. | A | 36337 | 761 | 01 янв 2023 г. |
| Dunne Michael W. | A | 3487 | 3487 | 23 дек 2022 г. |
| HUNT RONALD | A | 5479 | 5479 | 23 дек 2022 г. |
| Ahrens Brenton Karl | A | 29125 | 29125 | 23 дек 2022 г. |
| Puttagunta Sailaja | D | 4969 | 3365 | 02 дек 2022 г. |
| Puttagunta Sailaja | D | 24999 | 8334 | 01 дек 2022 г. |
| Puttagunta Sailaja | A | 8334 | 8334 | 01 дек 2022 г. |
Новостная лента
All You Need to Know About Iterum Therapeutics PLC (ITRM) Rating Upgrade to Strong Buy
Zacks Investment Research
13 апр 2023 г. в 13:39
Iterum Therapeutics PLC (ITRM) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Iterum Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023
GlobeNewsWire
09 мар 2023 г. в 17:00
DUBLIN, Ireland and CHICAGO, March 09, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its fourth quarter and fully year 2022 financial results before the open of the U.S. financial markets on Thursday, March 16, 2023. Management will host a conference call at 8:30 a.m. ET that day to discuss the Company's financial results and provide an update on its business.
Iterum Therapeutics plc (ITRM) Q3 2022 Earnings Call Transcript
Seeking Alpha
10 ноя 2022 г. в 11:42
Iterum Therapeutics plc (NASDAQ:ITRM ) Q3 2022 Earnings Conference Call November 10, 2022 8:30 AM ET Company Participants Louise Barrett – Senior Vice President-Legal Affairs Corey Fishman – Chief Executive Officer Judy Matthews – Chief Financial Officer Conference Call Participants Ed Acre – H.C. Wainwright Operator Ladies and gentlemen, welcome to the Iterum Therapeutics Third Quarter 2022 Financial Results Call.
Iterum Therapeutics to Present Data at IDWeek 2022
GlobeNewsWire
17 окт 2022 г. в 17:19
DUBLIN, Ireland and CHICAGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that two posters will be presented at the Infectious Disease Society of America's IDWeek 2022.
Iterum Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
GlobeNewsWire
07 сент 2022 г. в 09:15
DUBLIN, Ireland and CHICAGO, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that Corey Fishman, Chief Executive Officer, and Judy Matthews, Chief Financial Officer, will provide a company overview and business update at the H.C. Wainwright 24th Annual Hybrid Global Investment Conference at 12:00pm(ET) on Wednesday, September 14, 2022. Management will also host investor meetings on September 13-14, 2022.